Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2023-06-13 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯2022年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "annual equity distribution implementation announcement" for the year 2022 by 普莱柯生物工程股份有限公司. It details the dividend per share, relevant dates for dividend distribution, tax implications for different shareholder categories, and the approval of the distribution plan at the 2023 shareholders' meeting. The document is relatively short (3010 characters) and focuses on the announcement of dividend distribution details rather than presenting comprehensive financial statements or full annual report content. This matches the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2023-06-13 Chinese
北京德恒律师事务所关于普莱柯生物工程股份有限公司2022年年度股东大会的法律意见
Investor Presentation Classification · 85% confidence The document text contains only references to omitted pictures and no substantive text content. The total length is only 711 characters, which is very short and does not contain any financial data, report content, or detailed information. It appears to be a placeholder or a presentation with images only, likely related to a meeting or presentation material. Given the nature of the content (images/pictures) and the short length, it is most consistent with an Investor Presentation (IP) or AGM Information (AGM-R). However, since there is no explicit mention of an AGM or meeting, but multiple images which are typical for presentations, the best fit is Investor Presentation (IP). Confidence is high due to the lack of other content and the format.
2023-05-16 Chinese
普莱柯2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2022 Annual General Meeting (AGM) of 普莱柯生物工程股份有限公司, including voting results on various agenda items such as the 2022 annual report, board and supervisory reports, financial statements, profit distribution, and other corporate matters. It includes specifics on meeting attendance, voting percentages, and legal witness statements confirming the validity of the meeting and resolutions. The document is not the annual report itself but the official announcement of the AGM resolutions and voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3583 characters, which is consistent with an announcement rather than a full report.
2023-05-16 Chinese
普莱柯关于参加河南辖区上市公司2023年投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (480 characters) about the company's participation in an investor online collective reception day event scheduled for May 18, 2023. It includes details about the event, participants, and a web link for investors to join. There is no financial data, no report attached or referenced for download, and no mention of regulatory filings or certifications. The document is clearly an announcement related to investor relations activities but does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. It is not a report publication announcement since it does not mention any report release. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-05-11 Chinese
普莱柯2022年年度股东大会会议资料
AGM Information Classification · 95% confidence The document is titled '2022 年年度股东大会会议资料' which translates to '2022 Annual General Meeting (AGM) Meeting Materials'. It contains detailed information about the organization, agenda, voting procedures, and various reports to be discussed at the 2022 AGM of 普莱柯生物工程股份有限公司. The content includes the meeting schedule, voting methods, and summaries of reports such as the 2022 annual report, board work report, supervisory board report, independent directors' report, and other AGM-related materials. There is no indication that this is the full annual report itself, but rather the materials prepared for the AGM. The document length is substantial (15,000 characters), consistent with detailed AGM materials. Therefore, this document fits the category of AGM Information (AGM-R).
2023-05-09 Chinese
华泰联合证券有限责任公司关于普莱柯生物工程股份有限公司2022年持续督导年度报告书
Audit Report / Information Classification · 95% confidence The document is titled as a "2022 年持续督导年度报告书" which translates to "2022 Annual Continuous Supervision Report" by the sponsoring securities company for the listed company 普莱柯生物工程股份有限公司. It references regulatory frameworks such as the Securities Law, Shanghai Stock Exchange listing rules, and continuous supervision guidelines. The content details the continuous supervision activities performed by the sponsor, including review of information disclosure, compliance with laws and regulations, internal controls, and absence of violations or penalties during the supervision period. It is a report summarizing the sponsor's ongoing supervisory work rather than a full annual report or financial statement. The document length is 4737 characters, which is relatively short and focused on supervision activities. This type of document is a specialized regulatory report related to the sponsor's continuous supervision duties, which aligns with the category of Audit Report / Information (AR) as it involves audit-like oversight and compliance verification but is not a full annual report (10-K) or interim report (IR). It is not an announcement or certification, so it is not RPA or RNS. Therefore, the best classification is AR with high confidence.
2023-05-08 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.